{"id":263133,"date":"2020-07-28T00:22:13","date_gmt":"2020-07-28T04:22:13","guid":{"rendered":"https:\/\/canadianinquirer.net\/v1\/?p=263133"},"modified":"2020-07-28T00:22:13","modified_gmt":"2020-07-28T04:22:13","slug":"us-begins-final-tests-of-coronavirus-vaccine-candidate","status":"publish","type":"post","link":"https:\/\/canadianinquirer.net\/v1\/2020\/07\/28\/us-begins-final-tests-of-coronavirus-vaccine-candidate\/","title":{"rendered":"US begins final tests of coronavirus vaccine candidate"},"content":{"rendered":"
<\/div>\n
\"\"<\/a>
The vaccine efficacy trial is the first to be implemented under Operation Warp Speed, a governmental program that aims to begin delivering millions of doses of an effective virus vaccine by the end of 2020. (File photo: CDC\/Unsplash)<\/figcaption><\/figure>\n

ANKARA<\/strong>\u00a0\u2013 Phase-three trials began on Monday of a candidate vaccine against the novel coronavirus in the US, with an expected enrollment of 30,000 volunteers, the National Institutes of Health announced.<\/p>\n

The vaccine was co-developed by biotechnology company Moderna, Inc., based in Cambridge, Massachusetts, and the National Institute of Allergy and Infectious Diseases (NIAID).<\/p>\n

The trial will be conducted across 89 US clinical research sites with adult volunteers who do not have Covid-19, according to the statement.<\/p>\n

NIAID Director Anthony Fauci said results from earlier clinical testing indicated that the vaccine was “safe and immunogenic, supporting the initiation of Phase 3 clinical trial.”<\/p>\n

“This scientifically rigorous, randomized, placebo-controlled trial is designed to determine if the vaccine can prevent Covid-19 and for how long such protection may last.”<\/p>\n

The vaccine efficacy trial is the first to be implemented under Operation Warp Speed, a governmental program that aims to begin delivering millions of doses of an effective virus vaccine by the end of 2020.<\/p>\n

The trial is designed to determine if the vaccine can prevent symptomatic Covid-19 after two doses and it aims to study whether the vaccine can prevent severe infection with or without disease symptoms, the NIH said.<\/p>\n

It also seeks to answer whether the vaccine can prevent death caused by the virus and if just one dose can prevent symptomatic Covid-19, among other objectives.<\/p>\n

Trial volunteers will receive two injections approximately 28 days apart and some participants will be assigned at random to a control group that will be administered placebo doses.<\/p>\n

“The launch of this Phase 3 trial in record time while maintaining the most stringent safety measures demonstrates American ingenuity at its best and what can be done when stakeholders come together with unassailable objectivity toward a common goal,” NIH Director Francis Collins said.<\/p>\n

Investigators will use public health data and incidence trajectory modeling to identify sustained high-incidence areas and emerging hot zones, so sites near these locations can be prioritized for enrollment.<\/p>\n

The US government also backs the vaccine research of the Maryland-based Novavax biotechnology firm and Pfizer pharmaceutical corporation in New York City.<\/p>\n

The US is the worst-hit country by the pandemic with more than 4.2 million cases and nearly 147,000 deaths, according to a running tally of Johns Hopkins University. In all, nearly 1.3 million recoveries have been recorded.<\/p>\n

Many parts of the country have recently suffered new surges in virus cases.<\/p>\n","protected":false},"excerpt":{"rendered":"

ANKARA\u00a0\u2013 Phase-three trials began on Monday of a candidate vaccine against the novel coronavirus in the US, with an expected …<\/p>\n","protected":false},"author":33,"featured_media":261184,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16,17],"tags":[],"class_list":["post-263133","post","type-post","status-publish","format-standard","has-post-thumbnail","category-news","category-news-w","mauthors-anadolu","mauthors-philippine-news-agency"],"_links":{"self":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/263133","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/comments?post=263133"}],"version-history":[{"count":1,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/263133\/revisions"}],"predecessor-version":[{"id":263138,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/263133\/revisions\/263138"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media\/261184"}],"wp:attachment":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media?parent=263133"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/categories?post=263133"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/tags?post=263133"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}